🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today we are excited to virtually welcome our 2021 Graduate Student Symposium in Chemical Research winners! Every year, we recognize 8 outstanding Ph.D students in the fields of organic synthesis, chemical biology, or computational chemistry. bit.ly/2SKP5zv

Congrats Vishva bit.ly/2Qg7O4R

Charlie Fuchs, our Head of Oncology and Hematology for Global Product Development, shares how in recent years we've seen a revolution in cancer care therapies for the patients we serve. Hear from Charlie below. #ASCO21 bit.ly/2Tn3C4I

The Pharmacologist bit.ly/3rbBCh4

We’re pleased to announce the POLARIX study met its primary endpoint, demonstrating significantly improved progression-free survival in people with previously untreated diffuse large B-cell #lymphoma, or #DLBCL. Learn more: bit.ly/3g4KjWn

#WomenInSTEM Join AAPS in congratulating Saraswati R. Kenkare-Mitra, Ph.D., for receiving the 2021 Alice E. Till Advancement of Women in Pharmaceutical Sciences Recognition. She will be recognized during #PharmSci360: bit.ly/3yInlvR. Congratulations Saraswati!

Honored to receive this recognition from AAPS #PharmSci360

We are pioneering immuno-neurology as a new way to create medicines. Our immuno-neurology therapies recruit the central innate immune system to counteract brain pathologies. Learn more about how our approach works.

Congratulations to our Head of Corporate Development, Naveen Bazaj, for being selected as a 2022 Pharmaceutical Executive Emerging Pharma Leader! He is of the utmost deserving of this prestigious honor, and we are proud to have him on the Alector team.

#DYK 1 in 4 children in the #BayArea lives below the poverty line? We partnered with @FGTtweets again this year for their annual #backpackcomeback to help get backpacks & funds to students in need. Learn more about FGT's efforts: familygivingtree.org

We did it again! Alector is #11 on FORTUNE's #BestWorkplaces in Biopharma List. We continue to be committed to building an open, diverse and inclusive environment for all. Cheers to our team who made this honor possible once again. #GPTWcertified fortune.com/best-small-wor…

Today, we announced the initiation of the first-in-human Phase 1 trial of AL044, the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for #Alzheimers disease. Learn more about this study & AL044: investors.alector.com/news-releases/…

We're thrilled to share Alector is a finalist in California Life Sciences (CLS)' Pantheon Awards. Public voting is now open until October 14. Learn more ➡️ califesciences.org/pantheon-votin…

This week, we highlighted our collaboration with Women In Bio and hosted a panel discussion on navigating career journeys in biotech with Alectorian women leaders. Thank you to our inspiring Alectorians for sharing their stories!

We're thrilled to welcome Norah Conway on board as SVP, Portfolio, Program & Alliance Management. With more than 20 years of experience as a drug development professional managing global, multi-disciplinary project teams, Norah's expertise will be invaluable to Alector.

There is increasing awareness of the need for new #Alzheimers treatment approaches. Check out CEO Arnon Rosenthal's inclusion in this insightful piece from Ryan Cross the Science Boss for The Boston Globe .

Thanks Dr. Sue Desmond-Hellmann

It was my true honor to deliver this years commencement address at the UCSF school of pharmacy graduation ceremony today. Congrats to all the graduates- class of 2023! #ucsf #commencement #graduation2023 pharmacy.ucsf.edu/commencement

We're excited to share Dr. Sara Kenkare-Mitra has been named to San Francisco Business Times' Most Influential Women in Bay Area Business! Her expertise has been integral to the advancement of our clinical and early-stage neurodegeneration programs. Congratulations, Dr. Kenkare-Mitra!

Recently, improved neuroscience R&D has taken center stage in our industry. Our President & Head of R&D, Dr. Sara Kenkare-Mitra, joined other leaders on the #FierceBiotechSummit "Revival in Neuro Therapeutics" panel to discuss the evolving neurodegenerative therapeutic landscape.